Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

Press Release

Akari TX / September 27, 2022

Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing …

Akari TX / September 22, 2022

NEW YORK and LONDON, September 22, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

Akari TX / September 12, 2022

NEW YORK and LONDON, September 12, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

Akari TX / August 1, 2022

NEW YORK and LONDON, August 1, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …

Akari TX / July 28, 2022

Positive results from recent pre-clinical studies support the potential of long-acting PASylated® nomacopan to advance toward IND/IMPD for clinical trials in …

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

LONDON

NEW YORK

REGISTERED ADDRESS

EXPANDED ACCESS POLICY